Premium
Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure
Author(s) -
Jong Loek A. W.,
Elekonawo Fortuné M. K.,
Reuver Philip R.,
Bremers Andre J. A.,
Wilt Johannes H. W.,
Jansman Frank G. A.,
Heine Rob,
Erp Nielka P.
Publication year - 2019
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13773
Subject(s) - oxaliplatin , hyperthermic intraperitoneal chemotherapy , medicine , peritoneal carcinomatosis , cytoreductive surgery , pharmacokinetics , intraperitoneal chemotherapy , colorectal cancer , intensive care medicine , oncology , pharmacology , cancer , ovarian cancer
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care in the treatment of patients with peritoneal carcinomatosis of colorectal origin. The use of oxaliplatin for HIPEC has gained popularity. Although the HIPEC procedure is adopted throughout the world, major differences exist between treatment protocols regarding the carrier solution, perfusate volume, use of an open or closed technique, duration of the perfusion and application of additional flushing. These differences can influence the pharmacokinetics and pharmacodynamics of oxaliplatin and might thereby have an impact on the efficacy and/or safety of the treatment. Clinicians should be aware of the clinical importance of oxaliplatin pharmacology when performing HIPEC surgery. This review adds new insights into the complex field of the pharmacology of HIPEC and highlights an important worldwide problem: the lack of standardization of the HIPEC procedure.